Supernus Pharmaceuticals Inc (SUPN)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 73,865 | 59,712 | 5,239 | -15,508 | 1,316 | 25,622 | 43,347 | 52,043 | 60,711 | 37,672 | 57,485 | 73,346 | 53,424 | 81,750 | 100,185 | 111,126 | 126,950 | 129,311 | 118,174 | 116,234 |
| Total stockholders’ equity | US$ in thousands | 1,035,730 | 1,007,150 | 957,454 | 929,166 | 921,516 | 912,191 | 919,908 | 912,150 | 886,204 | 852,798 | 841,434 | 828,446 | 815,851 | 810,468 | 785,579 | 754,444 | 744,858 | 708,879 | 665,974 | 613,383 |
| ROE | 7.13% | 5.93% | 0.55% | -1.67% | 0.14% | 2.81% | 4.71% | 5.71% | 6.85% | 4.42% | 6.83% | 8.85% | 6.55% | 10.09% | 12.75% | 14.73% | 17.04% | 18.24% | 17.74% | 18.95% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $73,865K ÷ $1,035,730K
= 7.13%
Supernus Pharmaceuticals Inc's return on equity (ROE) has shown a declining trend from the first quarter of 2020 to the fourth quarter of 2024. The ROE decreased from 18.95% in March 2020 to 7.13% in December 2024.
The decreasing trend in ROE could indicate a decline in the company's profitability relative to its shareholders' equity over the period. Factors such as increasing costs, declining revenues, or inefficient use of assets could contribute to the decrease in ROE.
It is essential for investors and stakeholders to closely monitor Supernus Pharmaceuticals Inc's financial performance and investigate the reasons behind the declining ROE to assess the company's financial health and sustainability in the long term.
Peer comparison
Dec 31, 2024